Do analysts recommend CALT or LWAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, CALT or LWAC?

LightWave Acquisition has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Calliditas Therapeutics AB (publ) $1.60B 0.74 -$43.96M -$1.85 N/A LightWave Acquisition N/A N/A N/A N/A N/A

Do analysts prefer LWAC or AVTE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, LWAC or AVTE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is LWAC or AVTE more profitable?

LightWave Acquisition's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Aerovate Therapeutics N/A -90.19% -77.47%

Do analysts recommend LWAC or ELYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, LWAC or ELYM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is LWAC or ELYM more profitable?

LightWave Acquisition's return on equity of 0.00% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Eliem Therapeutics N/A -47.03% -45.97%

Do analysts rate LWAC or NLTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, LWAC or NLTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A

Is LWAC or NLTX more profitable?

LightWave Acquisition's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Neoleukin Therapeutics N/A -37.22% -30.91%

Do analysts rate LWAC or CNTN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, LWAC or CNTN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A

Is LWAC or CNTN more profitable?

LightWave Acquisition's return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Hillstream Biopharma N/A -31.50% -24.72%

LightWave Acquisition (LWAC) Competitors

$10.27 +0.01 (+0.08%)

Closing price 03:50 PM Eastern

Extended Trading

$10.24 -0.03 (-0.26%)

As of 04:01 PM Eastern

Compare

LWAC vs. CALT, AVTE, ELYM, NLTX, and CNTN

Should you buy LightWave Acquisition stock or one of its competitors? MarketBeat compares LightWave Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LightWave Acquisition include Calliditas Therapeutics AB (publ) (CALT), Aerovate Therapeutics (AVTE), Eliem Therapeutics (ELYM), Neoleukin Therapeutics (NLTX), and Hillstream Biopharma (CNTN).

How does LightWave Acquisition compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

LightWave Acquisition has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. LightWave Acquisition's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
LightWave Acquisition	N/A	N/A	N/A

In the previous week, LightWave Acquisition's average media sentiment score of 1.87 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that LightWave Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
LightWave Acquisition	Very Positive

LightWave Acquisition has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ).

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

LightWave Acquisition beats Calliditas Therapeutics AB (publ) on 5 of the 8 factors compared between the two stocks.

How does LightWave Acquisition compare to Aerovate Therapeutics?

LightWave Acquisition (NASDAQ:LWAC) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

LightWave Acquisition's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, LightWave Acquisition's average media sentiment score of 1.87 beat Aerovate Therapeutics' score of 0.00 indicating that LightWave Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
LightWave Acquisition	Very Positive
Aerovate Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Summary

LightWave Acquisition beats Aerovate Therapeutics on 4 of the 4 factors compared between the two stocks.

How does LightWave Acquisition compare to Eliem Therapeutics?

LightWave Acquisition (NASDAQ:LWAC) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, LightWave Acquisition's average media sentiment score of 1.87 beat Eliem Therapeutics' score of 0.00 indicating that LightWave Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
LightWave Acquisition	Very Positive
Eliem Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

LightWave Acquisition's return on equity of 0.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Eliem Therapeutics	N/A	-47.03%	-45.97%

Summary

LightWave Acquisition beats Eliem Therapeutics on 4 of the 6 factors compared between the two stocks.

How does LightWave Acquisition compare to Neoleukin Therapeutics?

LightWave Acquisition (NASDAQ:LWAC) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, LightWave Acquisition's average media sentiment score of 1.87 beat Neoleukin Therapeutics' score of 0.00 indicating that LightWave Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
LightWave Acquisition	Very Positive
Neoleukin Therapeutics	Neutral

LightWave Acquisition's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

LightWave Acquisition beats Neoleukin Therapeutics on 4 of the 6 factors compared between the two stocks.

How does LightWave Acquisition compare to Hillstream Biopharma?

LightWave Acquisition (NASDAQ:LWAC) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

1.2% of Hillstream Biopharma shares are held by institutional investors. 6.7% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

LightWave Acquisition's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Hillstream Biopharma	N/A	-31.50%	-24.72%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

In the previous week, Hillstream Biopharma had 1 more articles in the media than LightWave Acquisition. MarketBeat recorded 1 mentions for Hillstream Biopharma and 0 mentions for LightWave Acquisition. LightWave Acquisition's average media sentiment score of 1.87 beat Hillstream Biopharma's score of 0.94 indicating that LightWave Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
LightWave Acquisition	Very Positive
Hillstream Biopharma	Positive

Summary

LightWave Acquisition and Hillstream Biopharma tied by winning 3 of the 6 factors compared between the two stocks.

Get LightWave Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LWAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LWAC vs. The Competition

Export

Metric	LightWave Acquisition	Pharmaceutical Preparations Industry	Sector	NASDAQ Exchange
Market Cap	$308.57M	$931.03M	$2.85B	$12.35B
Dividend Yield	N/A	4.84%	15.23%	5.67%
P/E Ratio	N/A	1.43	14.97	24.25
Price / Sales	N/A	125.66	3,761.72	108.09
Price / Cash	N/A	20.06	52.47	56.68
Price / Book	N/A	7.92	5.84	6.69
Net Income	N/A	-$4.88M	-$220.64M	$337.12M
7 Day Performance	0.08%	2.09%	1.11%	1.78%
1 Month Performance	0.86%	1.63%	1.13%	3.64%
1 Year Performance	N/A	45.53%	15.90%	28.19%

LightWave Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LWAC LightWave Acquisition	N/A	$10.27 +0.1%	N/A	N/A	$308.57M	N/A	N/A	N/A	Positive News High Trading Volume
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
AVTE Aerovate Therapeutics	N/A	$15.34 -4.6%	N/A	+126.9%	$444.63M	N/A	N/A	20	Gap Up High Trading Volume
ELYM Eliem Therapeutics	N/A	$11.44 +4.9%	N/A	+807.9%	$340.36M	N/A	N/A	9
NLTX Neoleukin Therapeutics	N/A	$29.10 +0.3%	N/A	+47.3%	$273.48M	N/A	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LWAC) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LightWave Acquisition (LWAC) Competitors

LWAC vs. CALT, AVTE, ELYM, NLTX, and CNTN

How does LightWave Acquisition compare to Calliditas Therapeutics AB (publ)?

Summary

How does LightWave Acquisition compare to Aerovate Therapeutics?

Summary

How does LightWave Acquisition compare to Eliem Therapeutics?

Summary

How does LightWave Acquisition compare to Neoleukin Therapeutics?

Summary

How does LightWave Acquisition compare to Hillstream Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LWAC vs. The Competition

LightWave Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LightWave Acquisition (LWAC) Competitors

LWAC vs. CALT, AVTE, ELYM, NLTX, and CNTN

How does LightWave Acquisition compare to Calliditas Therapeutics AB (publ)?

Is CALT or LWAC more profitable?

Does the media prefer CALT or LWAC?

Which has preferable earnings and valuation, CALT or LWAC?

Do institutionals & insiders have more ownership in CALT or LWAC?

Do analysts recommend CALT or LWAC?

Summary

How does LightWave Acquisition compare to Aerovate Therapeutics?

Is LWAC or AVTE more profitable?

Does the media refer more to LWAC or AVTE?

Do analysts prefer LWAC or AVTE?

Which has better earnings and valuation, LWAC or AVTE?

Summary

How does LightWave Acquisition compare to Eliem Therapeutics?

Do insiders and institutionals believe in LWAC or ELYM?

Does the media refer more to LWAC or ELYM?

Do analysts recommend LWAC or ELYM?

Which has stronger earnings and valuation, LWAC or ELYM?

Is LWAC or ELYM more profitable?

Summary

How does LightWave Acquisition compare to Neoleukin Therapeutics?

Which has higher earnings & valuation, LWAC or NLTX?

Do insiders and institutionals have more ownership in LWAC or NLTX?

Do analysts rate LWAC or NLTX?

Does the media refer more to LWAC or NLTX?

Is LWAC or NLTX more profitable?

Summary

How does LightWave Acquisition compare to Hillstream Biopharma?

Do institutionals & insiders have more ownership in LWAC or CNTN?

Do analysts rate LWAC or CNTN?

Is LWAC or CNTN more profitable?

Which has better earnings and valuation, LWAC or CNTN?

Does the media prefer LWAC or CNTN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LWAC vs. The Competition

LightWave Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools